Orthofix MedicalOFIX
OFIX
About: Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.
Employees: 1,616
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
7% more funds holding
Funds holding: 149 [Q4 2024] → 159 (+10) [Q1 2025]
2% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 52
1.43% less ownership
Funds ownership: 86.49% [Q4 2024] → 85.05% (-1.43%) [Q1 2025]
6% less capital invested
Capital invested by funds: $577M [Q4 2024] → $541M (-$35.7M) [Q1 2025]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 4 (-1) [Q1 2025]
78% less call options, than puts
Call options by funds: $8K | Put options by funds: $36K
Research analyst outlook
We haven’t received any recent analyst ratings for OFIX.
Financial journalist opinion
Neutral
Seeking Alpha
1 month ago
Orthofix Medical Inc. (OFIX) Q1 2025 Earnings Call Transcript
Orthofix Medical Inc. (NASDAQ:OFIX ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Julie Dewey - Chief Investor Relations and Communications Officer Massimo Calafiore - President and Chief Executive Officer Julie Andrews - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Caitlin Cronin - Canaccord Genuity Jeffrey Cohen - Ladenburg Operator Thank you for standing by. My name is Tina, and I will be your conference operator today.
Negative
Zacks Investment Research
1 month ago
Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates
Orthofix (OFIX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.46 per share a year ago.
Neutral
Business Wire
1 month ago
Orthofix Reports First Quarter 2025 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product.
Neutral
Business Wire
2 months ago
Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the European CE Mark for the TrueLok™ Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate provides a limb preservation treatment option for addressing bony or soft tissue deformities and defects such as diabetic foot ulcers and nonhealing or deep tissue wounds. While the TBT.
Neutral
GlobeNewsWire
2 months ago
Kuehn Law Encourages Investors of Orthofix Medical Inc. to Contact Law Firm
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Orthofix Medical Inc. (NASDAQ: OFIX) breached their fiduciary duties to shareholders.
Neutral
Business Wire
3 months ago
Orthofix Announces Appointment of Vickie Capps to Board of Directors
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. “Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix,” said Michael Finegan, Chairman of Orthofix. “Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously.
Neutral
Business Wire
3 months ago
Orthofix to Participate in the 37th Annual Roth Conference
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the 37th Annual Roth Conference in Dana Point, CA. Management is scheduled to present on Monday, March 17, 2025 at 8:00 am PT. Interested parties can access the live and archived webcast of the presentation in the “Events & Presentations” section of the Orthofix investor relations website at ir.orthofix.com. Internet Posti.
Neutral
Seeking Alpha
3 months ago
Orthofix Medical Inc. (OFIX) Q4 2024 Earnings Call Transcript
Orthofix Medical Inc. (OFIX) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
3 months ago
Orthofix (OFIX) Q4 Earnings Lag Estimates
Orthofix (OFIX) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.10 per share a year ago.
Neutral
Business Wire
3 months ago
Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year 2025 financial guidance. Highlights Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023 U.S. Spine Fixation1 net sales growth of 12% compared to fourth quarter 202.
Charts implemented using Lightweight Charts™